List of Makena drug patents

Makena is owned by Covis.

Makena contains Hydroxyprogesterone Caproate.

Makena has a total of 12 drug patents out of which 0 drug patents have expired.

Makena was authorised for market use on 03 February, 2011.

Makena is available in solution;subcutaneous, solution;intramuscular dosage forms.

Makena can be used as reducing the risk of preterm birth in women with a singleton pregnancy who have a history of singleton spontaneous preterm birth.

The generics of Makena are possible to be released after 02 May, 2036.

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11446441 COVIS Prefilled syringe injector
Jan, 2026

(2 years from now)

US9533102 COVIS Prefilled syringe jet injector
Jan, 2026

(2 years from now)

US9180259 COVIS Prefilled syringe jet injector
Jan, 2026

(2 years from now)

US8562564 COVIS Prefilled syringe jet injector
Jan, 2026

(2 years from now)

US9629959 COVIS Prefilled syringe jet injector
Jan, 2026

(2 years from now)

US8021335 COVIS Prefilled syringe jet injector
Oct, 2026

(3 years from now)

US11446440 COVIS Needle assisted injection device having reduced trigger force
Aug, 2031

(8 years from now)

US9789257 COVIS Needle assisted injection device having reduced trigger force
Feb, 2034

(11 years from now)

US11154562 COVIS Methods of reducing risk of preterm birth
May, 2036

(13 years from now)

US9844558 COVIS Methods of reducing risk of preterm birth
May, 2036

(13 years from now)

US11304962 COVIS Methods of reducing risk of preterm birth
May, 2036

(13 years from now)

US10471075 COVIS Methods of reducing risk of preterm birth
May, 2036

(13 years from now)

Drugs and Companies using HYDROXYPROGESTERONE CAPROATE ingredient

Market Authorisation Date: 03 February, 2011

Treatment: Reducing the risk of preterm birth in women with a singleton pregnancy who have a history of singleton spontaneous preterm birth

Dosage: SOLUTION;INTRAMUSCULAR; SOLUTION;SUBCUTANEOUS

How can I launch a generic of MAKENA before it's patent expiration?
More Information on Dosage

availability in other generic markets.

Click on the highlighted region to filter.

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic